Detection Rate of Recurrent Medullary Thyroid Carcinoma Using Fluorine-18 Dihydroxyphenylalanine Positron Emission Tomography. A Meta-analysis

Academic Radiology

Volumn 19, Issue 10, 2012, Pages 1290-1299

  Treglia, Giorgio ^a   Cocciolillo, Fabrizio ^a   Di Nardo, Francesco ^a   Poscia, Andrea ^a   de Waure, Chiara ^a   Giordano, Alessandro ^a   Rufini, Vittoria ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

18F DOPA; Dihydroxyphenylalanine; Medullary thyroid carcinoma; PET CT; Positron emission tomography

Indexed keywords

6 FLUORODOPA F 18; CALCITONIN; CARBIDOPA; CARCINOEMBRYONIC ANTIGEN;

CALCITONIN BLOOD LEVEL; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EMBASE; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RECURRENT CANCER; RECURRENT MEDULLARY THYROID CARCINOMA; REVIEW; SYSTEMATIC REVIEW; THYROID MEDULLARY CARCINOMA;

DIHYDROXYPHENYLALANINE; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 84865709685     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2012.05.008     Document Type: Review

References (20)

1. Pitt S.C., Moley J.F. Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol 2010, 37:567-579.
2. Kloos R.T., Eng C., Evans D.B., et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612. American Thyroid Association Guidelines Task Force.
3. Rufini V., Treglia G., Perotti G., et al. Role of PET in medullary thyroid carcinoma. Minerva Endocrinol 2008, 33:67-73.
4. Rufini V., Castaldi P., Treglia G., et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother 2008, 62:139-146.
5. Jager P.L., Chirakal R., Marriott C.J., et al. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. J Nucl Med 2008, 49:573-586.
6. Whiting P.F., Rutjes A.W., Westwood M.E., et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011, 155:529-536.
7. Zamora J., Abraira V., Muriel A., et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006, 6:31.
8. Kauhanen S., Seppänen M., Ovaska J., et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 2009, 16:255-265.
9. Treglia G., Castaldi P., Villani M.F., et al. Comparison of (18)F-DOPA, (18)F-FDG and (68)Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2012, 39:569-580.
10. Kauhanen S., Schalin-Jäntti C., Seppänen M., et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med 2011, 52:1855-1863.
11. Luster M., Karges W., Zeich K., et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010, 20:527-533.
12. Marzola M.C., Pelizzo M.R., Ferdeghini M., et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol 2010, 36:414-421.
13. Beheshti M., Pöcher S., Vali R., et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 2009, 19:1425-1434.
14. Koopmans K.P., de Groot J.W., Plukker J.T., et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008, 49:524-531.
15. Beuthien-Baumann B., Strumpf A., Zessin J., et al. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007, 34:1604-1609.
16. Hoegerle S., Altehoefer C., Ghanem N., et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001, 28:64-71.
17. Treglia G., Castaldi P., Rindi G., et al. Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 2012, Feb 20, Epub ahead of print.
18. Conry B.G., Papathanasiou N.D., Prakash V., et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010, 37:49-57.
19. Pałyga I., Kowalska A., Gasior-Perczak D., et al. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol 2010, 61:507-511.
20. Treglia G., Villani M.F., Giordano A., et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine 2012, Apr 17, Epub ahead of print.